MARKET WIREFintel • 2d ago
Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action IndicatedWhy RDY Stock slipped -0.28% Today — RQD Quant Desk Flash
$14.11 -0.28% NYSE • Public Delayed / 60s Snapshot
Dr. Reddy's Laboratories Ltd (RDY) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $11.78B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+3.1% Base Target
WHALE OPTIONS TUG-OF-WAR:53% Call Buyers ($2.4M)
47% PutsMax Pain: $14.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RDY Stock slipped -0.28% Today — RQD Quant Desk Flash
Dr. Reddy's Laboratories Ltd (RDY) slipped -0.28% to $14.11 as options desks priced 53% call premium vs. 47% put protection around the $14 max-pain magnet. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 64% of its 52-week range ($11.36 – $15.67) with RSI-14 at 77.7 (OVERBOUGHT (>70)).
- ▸Whale Options Positioning: $2.4M in bullish call flow vs. $2.1M in put flow (Put/Call 0.89x, implied earnings swing ±7.1%).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 41% gross margin and $260.3M annual free cash flow.
Live RDY Headlines & Catalysts
RISK WATCHYahoo • 5d ago
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallDr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
MARKET WIRESeekingAlpha • 8d ago
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call TranscriptMARKET WIREFintel • 8d ago
Dr. Reddy's Laboratories Limited Reports Q2 FY 2027 Financial ResultsMARKET WIREFintel • 8d ago
Dr. Reddy's Laboratories Limited Appoints Akhil Ravi as Head API and Services Effective November 13, 2026MARKET WIREYahoo • 8d ago
Dr. Reddy's Laboratories Q2 Earnings Call HighlightsDr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset gr
MARKET WIREFintel • 8d ago
Dr. Reddy's Laboratories Limited Reports Revenues of Rs. 86,708 Million for the Quarter Ended September 30, 2026MARKET WIREBenzinga • 8d ago
Dr Reddy's Laboratories Q2 2027 Earnings Call TranscriptDr Reddy’s Laboratories (NYSE:RDY) reported second-quarter financial results on Friday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by
RISK WATCHBenzinga • 9d ago
Dr Reddy's Laboratories Q2 EPS $0.12 Misses $0.16 Estimate, Sales $905.000M Miss $980.650M EstimateDr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.16 by 25 percent. This is a 36.84 percent decrease over earnings of $0.19 per share
MARKET WIREBenzinga • 9d ago
'Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption' - Reutershttps://www.reuters.com/legal/litigation/dr-reddys-rolls-out-new-generic-ozempic-brands-amid-obeda-supply-disruption-2026-10-23/
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live RDY Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
RDY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.89%▲ RESISTANCE BREAKOUT
2026-10-30O $14.20H $14.31L $14.15C $14.17VOL 1.83M
RES: $13.27SUP: $11.64SMA50: $12.54SMA200: $13.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RDY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RDY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RDY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RDY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
RDY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RDY stock moving today?
Why RDY Stock slipped -0.28% Today — RQD Quant Desk Flash. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.